Search
for
Sort by
Research 30 of 1000+
- Selective non-steroidal inhibitors of 5α-reductase type 1
- The Mechanisms of Anabolic Steroids, Selective Androgen Receptor Modulators and Myostatin Inhibitors
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 467 Novel selective phosphodiesterase inhibitors promote the adipogenic function of dermal fibroblasts: Implication to treat hair loss
- Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors
- Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)
- Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
- Selective induction of apoptosis in the hamster flank sebaceous gland organ by a topical liposome 5-α-reductase inhibitor: A treatment strategy for acne
- Benzo[<i>c</i>]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Several Selective Protein Kinase C Inhibitors Including Procyanidins Promote Hair Growth
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats].
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- Strontium: A Potent and Selective Inhibitor of Sensory Irritation and Topical Anti-inflammatory
- LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Intraoperative Iris Behavior during Phacoemulsification Maneuvers in Rabbits Treated with Selective α1-Blocker, 5α-Reductase Inhibitor, or Anxiolytic Medication
- The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights
- Nipple Differentiation in Fetal Male Rats Treated with an Inhibitor of the Enzyme 5<i>α</i>-Reductase: Definition of a Selective Role for Dihydrotestosterone*
- Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
- Effect of C-ring modifications in benzo[c]quinolizin-3-ones, new selective inhibitors of human 5α-reductase 1
- Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia